PAX8/PPARγ fusion is present in 35% of FTC tumors on average, can be overexpressed by up to 50-fold compared with endogenous PPARγ in tumor tissues [135, 136] and is probably the effector component of the oncogenic rearrangement [137]. The gene discussed is PPARG; the disease is neoplasm.